摘要
目的:分析和了解医院产超广谱β-内酰胺酶(extended-spectrum beta lactamase,ESBLs)肺炎克雷伯菌(Klebsiella pneumoniae,KP)感染的科室分布及其耐药现状,为临床合理用药提供参考。方法:抽取2019年度医院临床送检的患者标本中目标性监测分离出的感染KP菌株资料,统计其产ESBLs KP菌株的科室分布和感染病例的耐药实施监控现状,分析其药敏试验结果。结果:检测发现415株KP资料中,产ESBLs KP有41株,其检出率为9.88%;其中耐碳青霉烯类肺炎克雷伯菌(carbapenem-resistant Klebsiella pneumoniae,CRKP)4株,其检出率为0.96%;且其对抗菌药物的耐药率较高,但院内感染中未发生产ESBLs KP的爆发和流行。结论:临床检出产ESBLs KP分离株数较少,但耐药率较高;临床应重视产ESBLs KP感染病例的实施监控和抗菌药物使用的干预管理,以遏制其多重耐药菌株的产生,控制其院内感染。
Objective:To analyze and to know the distribution and drug resistance of producing extended spectrum beta-lactamase(ESBLs)infected Klebsiella pneumoniae(KP)in our hospital,and to provide reference for clinical rational drug use.Methods:The data of 415 strains of KP infection isolated from the samples of patients clinically tested in2019 were extracted,the department distribution of the strains producing ESBLs KP and the current situation of drug resistance monitoring in infection cases were calculated,and the drug sensitivity test results were analyzed.Results:It was found that among 415 strains of KP,41 strains produced ESBLs KP,with a detection rate of 9.88%.The detection rate of 4 strains of Carbapenem-resistant Klebsiella pneumoniae(CRKP)was 0.96%.It had a high resistance rate to antimicrobial agents,but there was no outbreak or epidemic of ESBLs KP production in nosocomial infections.Conclusion:The number of ESBLs KP isolates produced in clinical tests was less,but the drug resistance rate was higher.Clinical attention should be paid to the monitoring of ESBLs KP infection cases and the intervention management of antibacterial drug use,so as to curb the production of multidrug-resistant strains and control the occurrence of the nosocomial infection.
作者
周长鑫
ZHOU Chang-xin(Liping County People’s Hospital,Liping Guizhou 557300,China)
出处
《抗感染药学》
2020年第11期1578-1582,共5页
Anti-infection Pharmacy